YOKNEAM, Israel, Nov. 2, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2023.
Third Quarter 2023 Highlights:
U.S. GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q3 2023 | Q3 2022 | |
Revenues | $123,112 | $121,232 |
Gross Margins | 84 % | 85 % |
Net Income | $46,520 | $48,789 |
Earnings per Diluted Share | $0.54 | $0.58 |
*Non-GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q3 2023 | Q3 2022 | |
Gross Margins | 84 % | 85 % |
Net Income | $53,084 | $56,646 |
Earnings per Diluted Share | $0.61 | $0.66 |
*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.
Management Comments
"The third quarter was the first time that we experienced a slowdown, which was mainly attributed to a strong seasonality impact. In addition, record-high interest rates affected new leasing agreements and platform sale cycles were longer than usual," said Moshe Mizrahy, Chairman and Chief Executive Officer. "However, we are pleased to see high demand for InMode's treatments, as reflected by year-over-year consumables growth higher than 20%."
Shakil Lakhani, President of InMode North America, commented, "This quarter, the soft launch of Envision continued to gain traction in the U.S., and we were pleased to see the increased adoption level by both ophthalmologists and optometrists."
"As we mentioned last quarter, we are in the process of developing new and improved minimally invasive technologies and platforms as well as upgrading and adding new features to Morpheus8 and Evolve," said Dr. Spero Theodorou, Chief Medical Officer.
Third Quarter 2023 Financial Results
Total revenues for the third quarter of 2023 reached $123.1 million, an increase of 2% compared to the third quarter of 2022.
"Although we experienced some headwinds in the U.S., we are encouraged by our international sales, which increased by 13% in the third quarter of 2023 compared to the third quarter of 2022," said Yair Malca, Chief Financial Officer.
GAAP and *Non-GAAP gross margin for the third quarter of 2023 was 84% compared to a gross margin of 85% for the third quarter 2022.
GAAP operating margin for the third quarter of 2023 was 38%, compared to an operating margin of 44% in the third quarter of 2022. *Non-GAAP operating margin for the third quarter of 2023 was 43% compared to 51% for the third quarter of 2022. This decrease was primarily attributable to higher sales and marketing expenses, mainly because of the addition of new sales representatives, higher travel expenses, as well as investment in direct-to-consumer advertising campaigns and hosting in-person events to support the company's growth projections.
InMode reported GAAP net income of $46.5 million, or $0.54 per diluted share, in the third quarter of 2023, compared to $48.8 million, or $0.58 per diluted share, in the third quarter of 2022. On a *non-GAAP basis, InMode reported net income of $53.1 million, or $0.61 per diluted share, in the third quarter of 2023, compared to $56.6 million, or $0.66 per diluted share, in the third quarter of 2022.
2023 Financial Outlook
Management provided an outlook for the full year of 2023 ending December 31, 2023. Based on current estimates, management expects:
This outlook is not a guarantee of future performance and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.
*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.
The Current Situation in Israel
Regarding the current situation in Israel, management would like to assure investors that the Company is prioritizing the safety and well-being of its employees, and all its team are safe. InMode doesn't anticipate any interruption or delay in production or shipment. InMode's inventory levels globally and in Israel are sufficient and include components and subassemblies for at least 6 months.
Use of Non-GAAP Financial Measures
In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, and non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.
Conference Call Information
Mr. Moshe Mizrahy, Chairman and Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will host a conference call today, November 02, 2023, at 8:30 a.m. Eastern Time to discuss the third quarter 2023 financial results.
The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10183086/fa97575b36.
Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.
For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.
U.S. Toll-Free Dial-in Number: 1-833-316-0562
Israel Toll- Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5736
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
3:30 p.m. Israel Time
The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from November 02, 2023, at 12 p.m. Eastern Time to November 16, 2023, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:
Replay Dial-in U.S TOLL-FREE: 1-877-344-7529
Replay Dial-in Canada TOLL-FREE: 855-669-9658
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 2198302
To access the replay using an international dial-in number, please select the link below: https://services.choruscall.com/ccforms/replay.html
A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the future performance described above under the heading titled "2023 Financial Outlook." Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 14, 2023, as well as risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Relations Contact: Miri Segal MS-IR LLC Phone: (917) 607-8654 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
INMODE LTD. | |||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||
(U.S. dollars in thousands, except for per share data) | |||||
(Unaudited) | |||||
Three months ended | Nine months ended | ||||
2023 | 2022 | 2023 | 2022 | ||
REVENUES | 123,112 | 121,232 | 365,267 | 320,700 | |
COST OF REVENUES | 20,136 | 18,765 | 60,444 | 52,483 | |
GROSS PROFIT | 102,976 | 102,467 | 304,823 | 268,217 | |
OPERATING EXPENSES: | |||||
Research and development | 3,268 | 3,166 | 9,937 | 9,164 | |
Sales and marketing | 50,819 | 43,062 | 143,591 | 113,564 | |
General and administrative | 2,479 | 2,494 | 6,879 | 7,533 | |
TOTAL OPERATING EXPENSES | 56,566 | 48,722 | 160,407 | 130,261 | |
INCOME FROM OPERATIONS | 46,410 | 53,745 | 144,416 | 137,956 | |
Finance income (expense), net | 4,953 | 189 | 12,687 | (350) | |
INCOME BEFORE TAXES | 51,363 | 53,934 | 157,103 | 137,606 | |
INCOME TAXES | 4,843 | 5,145 | 14,349 | 13,794 | |
NET INCOME | 46,520 | 48,789 | 142,754 | 123,812 | |
NET INCOME PER SHARE: | |||||
Basic | 0.56 | 0.59 | 1.71 | 1.50 | |
Diluted | 0.54 | 0.58 | 1.66 | 1.45 | |
WEIGHTED AVERAGE NUMBER OF SHARES | |||||
Basic | 83,703 | 82,306 | 83,423 | 82,494 | |
Diluted | 85,970 | 84,823 | 85,814 | 85,120 | |
INMODE LTD. | ||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||
(U.S. dollars in thousands, except for per share data) | ||
(Unaudited) | ||
September 30, 2023 | December 31, 2022 | |
Assets | ||
CURRENT ASSETS: | ||
Cash and cash equivalents | 133,733 | 97,540 |
Marketable securities | 385,860 | 374,589 |
Short-term bank deposits | 156,253 | 75,254 |
Accounts receivable, net of allowance for doubtful accounts | 42,692 | 26,997 |
Other receivables | 19,385 | 15,094 |
Inventories | 39,989 | 39,897 |
TOTAL CURRENT ASSETS | 777,912 | 629,371 |
NON-CURRENT ASSETS: | ||
Accounts receivable, net of allowance for doubtful accounts | 4,074 | 3,973 |
Deferred income tax asset, net | 2,103 | 3,094 |
Operating lease right-of-use assets | 6,359 | 5,073 |
Property and equipment, net | 2,482 | 2,298 |
Other investments | 600 | 600 |
TOTAL NON-CURRENT ASSETS | 15,618 | 15,038 |
TOTAL ASSETS | 793,530 | 644,409 |
Liabilities and shareholders' equity | ||
CURRENT LIABILITIES: | ||
Accounts payable | 12,333 | 16,242 |
Contract liabilities | 10,625 | 13,798 |
Other liabilities | 39,230 | 51,980 |
TOTAL CURRENT LIABILITIES | 62,188 | 82,020 |
NON-CURRENT LIABILITIES: | ||
Contract liabilities | 3,502 | 3,959 |
Other liabilities | 762 | 303 |
Operating lease liabilities | 3,581 | 3,509 |
TOTAL NON-CURRENT LIABILITIES | 7,845 | 7,771 |
TOTAL LIABILITIES | 70,033 | 89,791 |
TOTAL SHAREHOLDERS' EQUITY | 723,497 | 554,618 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 793,530 | 644,409 |
INMODE LTD. | ||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
(U.S. dollars in thousands, except for per share data) | ||||||
(Unaudited) | ||||||
Three months ended | Nine months ended | |||||
2023 | 2022 | 2023 | 2022 | |||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income | 46,520 | 48,789 | 142,754 | 123,812 | ||
Adjustments required to reconcile net income to net cash provided by operating activities: | ||||||
Depreciation and amortization | 129 | 169 | 501 | 462 | ||
Share-based compensation expenses | 6,564 | 7,857 | 17,278 | 17,304 | ||
Allowance for doubtful accounts | 426 | 50 | 665 | 402 | ||
Loss on marketable securities, net | - | 12 | - | 49 | ||
Finance expenses (income), net | (527) | 586 | (3,236) | 1,527 | ||
Deferred income taxes, net | (216) | 9 | (154) | 156 | ||
Changes in operating assets and liabilities: | ||||||
Increase in accounts receivable | (10,753) | (6,926) | (16,461) | (11,220) | ||
Decrease (increase) in other receivables | (1,347) | 887 | (5,367) | (706) | ||
Increase in inventories | (1,421) | (6,050) | (92) | (14,784) | ||
Increase (decrease) in accounts payable | (962) | 1,463 | (3,909) | 4,517 | ||
Increase (decrease) in other liabilities | 3,040 | 4,136 | (12,792) | 3,366 | ||
Decrease in contract liabilities | (9) | (5,390) | (3,630) | (459) | ||
Net cash provided by operating activities | 41,444 | 45,592 | 115,557 | 124,426 | ||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Investment in short-term deposits | (179,140) | (48,090) | (285,140) | (93,701) | ||
Proceeds from short-term deposits | 91,590 | 30,090 | 204,090 | 73,090 | ||
Purchase of fixed assets | (149) | (387) | (684) | (1,247) | ||
Purchase of marketable securities | (60,588) | (58,982) | (233,130) | (97,736) | ||
Proceeds from sale of marketable securities | - | 301 | - | 2,303 | ||
Proceeds from maturity of marketable securities | 78,465 | 20,935 | 230,493 | 46,092 | ||
Net cash used in investing activities | (69,822) | (56,133) | (84,371) | (71,199) | ||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Repurchase of ordinary shares | - | - | - | (42,637) | ||
Exercise of options | 2,729 | 550 | 5,229 | 915 | ||
Net cash provided by (used in) financing activities | 2,729 | 550 | 5,229 | (41,722) | ||
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (473) | (1,365) | (222) | (2,593) | ||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (26,122) | (11,356) | 36,193 | 8,912 | ||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 159,855 | 88,404 | 97,540 | 68,136 | ||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 133,733 | 77,048 | 133,733 | 77,048 | ||
INMODE LTD. | ||||||||
CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS | ||||||||
(U.S. dollars in thousands, except for per share data) | ||||||||
(Unaudited) | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
Revenues by Category: | ||||||||
Capital Equipment revenues - United States | 67,969 | 55 % | 72,920 | 60 % | 191,548 | 53 % | 180,640 | 57 % |
Capital Equipment revenues - International | 37,276 | 30 % | 34,383 | 28 % | 114,284 | 31 % | 97,126 | 30 % |
Total Capital Equipment revenues | 105,245 | 85 % | 107,303 | 88 % | 305,832 | 84 % | 277,766 | 87 % |
Consumables and service revenues | 17,867 | 15 % | 13,929 | 12 % | 59,435 | 16 % | 42,934 | 13 % |
Total Net Revenue | 123,112 | 100 % | 121,232 | 100 % | 365,267 | 100 % | 320,700 | 100 % |
Three months ended September 30, | Nine months ended September 30, | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
% | % | % | % | |||||||||
United | Internati | Total | United | Internati | Total | United | Internati | Total | United | Internati | Total | |
Revenues by Technology: | ||||||||||||
Minimal-Invasive | 85 | 80 | 83 | 84 | 75 | 82 | 87 | 76 | 83 | 84 | 73 | 80 |
Hands-Free | 11 | 4 | 9 | 13 | 8 | 11 | 10 | 5 | 8 | 13 | 7 | 11 |
Non-Invasive | 4 | 16 | 8 | 3 | 17 | 7 | 3 | 19 | 9 | 3 | 20 | 9 |
100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
INMODE LTD. | |||||||
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF | |||||||
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||
(U.S. dollars in thousands, except for per share data) | |||||||
(Unaudited) | |||||||
Three months ended September 30, 2023 | Three months ended September 30, 2022 | ||||||
GAAP | Share Based | Non-GAAP | GAAP | Share Based | Non-GAAP | ||
REVENUES | 123,112 | - | 123,112 | 121,232 | - | 121,232 | |
COST OF REVENUES | 20,136 | (572) | 19,564 | 18,765 | (554) | 18,211 | |
GROSS PROFIT | 102,976 | 572 | 103,548 | 102,467 | 554 | 103,021 | |
OPERATING EXPENSES: | |||||||
Research and development | 3,268 | (729) | 2,539 | 3,166 | (857) | 2,309 | |
Sales and marketing | 50,819 | (4,787) | 46,032 | 43,062 | (5,879) | 37,183 | |
General and administrative | 2,479 | (476) | 2,003 | 2,494 | (567) | 1,927 | |
TOTAL OPERATING |
56,566 |
(5,992) |
50,574 |
48,722 |
(7,303) |
41,419 | |
INCOME FROM OPERATIONS | 46,410 | 6,564 | 52,974 | 53,745 | 7,857 | 61,602 | |
Finance income, net |
4,953 |
- |
4,953 |
189 |
189 | ||
INCOME BEFORE TAXES | 51,363 | 6,564 | 57,927 | 53,934 | 7,857 | 61,791 | |
INCOME TAXES | 4,843 | - | 4,843 | 5,145 | - | 5,145 | |
NET INCOME | 46,520 | 6,564 | 53,084 | 48,789 | 7,857 | 56,646 | |
NET INCOME PER SHARE: | |||||||
Basic | 0.56 | 0.63 | 0.59 | 0.69 | |||
Diluted | 0.54 | 0.61 | 0.58 | 0.66 | |||
WEIGHTED AVERAGE NUMBER OF | |||||||
Basic | 83,703 | 83,703 | 82,306 | 82,306 | |||
Diluted | 85,970 | 86,333 | 84,823 | 85,453 | |||
INMODE LTD. | ||||||
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF | ||||||
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||||||
(U.S. dollars in thousands, except for per share data) | ||||||
(Unaudited) | ||||||
Nine months ended September 30, 2023 | Nine months ended September 30, 2022 | |||||
GAAP | Share Based | Non-GAAP | GAAP | Share Based | Non-GAAP | |
REVENUES | 365,267 | - | 365,267 | 320,700 | - | 320,700 |
COST OF REVENUES | 60,444 | (1,473) | 58,971 | 52,483 | (1,364) | 51,119 |
GROSS PROFIT | 304,823 | 1,473 | 306,296 | 268,217 | 1,364 | 269,581 |
OPERATING EXPENSES: | ||||||
Research and development | 9,937 | (1,987) | 7,950 | 9,164 | (2,248) | 6,916 |
Sales and marketing | 143,591 | (12,556) | 131,035 | 113,564 | (12,233) | 101,331 |
General and administrative | 6,879 | (1,262) | 5,617 | 7,533 | (1,459) | 6,074 |
TOTAL OPERATING EXPENSES | 160,407 | (15,805) | 144,602 | 130,261 | (15,940) | 114,321 |
INCOME FROM OPERATIONS | 144,416 | 17,278 | 161,694 | 137,956 | 17,304 | 155,260 |
Finance income (expense),net | 12,687 | - | 12,687 | (350) | - | (350) |
INCOME BEFORE TAXES | 157,103 | 17,278 | 174,381 | 137,606 | 17,304 | 154,910 |
INCOME TAXES | 14,349 | - | 14,349 | 13,794 | - | 13,794 |
NET INCOME | 142,754 | 17,278 | 160,032 | 123,812 | 17,304 | 141,116 |
NET INCOME PER | ||||||
Basic | 1.71 | 1.92 | 1.50 | 1.71 | ||
Diluted | 1.66 | 1.86 | 1.45 | 1.65 | ||
WEIGHTED AVERAGE NUMBER OF | ||||||
Basic | 83,423 | 83,423 | 82,494 | 82,494 | ||
Diluted | 85,814 | 86,154 | 85,120 | 85,667 | ||
| Last Trade: | US$17.08 |
| Daily Change: | -0.11 -0.64 |
| Daily Volume: | 1,912,263 |
| Market Cap: | US$1.300B |
September 04, 2024 August 06, 2024 July 31, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
